Skip to main content
. 2020 Sep 22;58(10):e01032-20. doi: 10.1128/JCM.01032-20

TABLE 3.

Diagnostic performance of sputum-based Xpert MTB/RIF and urine-based Alere LAM testing in patients with CD4 counts of ≤50 and ≤200 cells/mm3a

Reference standard CD4 count (cells/mm3) Test strategyb % (95% CI)
Sensitivity Specificity PPV NPV
Sputum culture positivity ≤50 Xpert MTB/RIF only 81.5 (71.3–89.2) 94.3 (89.1–97.5) 89.2 (79.8–95.2) 89.9 (83.8–94.2)
Urine LAM test only 60.0 (47.1–72.0) 81.7 (72.9–88.6) 67.2 (53.7–79.0) 76.6 (67.6–84.1)
Sequential or concurrent testing 89.2 (79.1–95.6) 79.8 (70.8–87.0) 73.4 (62.3–82.7) 92.2 (84.6–96.8)
≤200 Xpert MTB/RIF Only 80.3 (72.3–86.8) 94.9 (91.3–97.3) 89.5 (82.3–94.4) 90.0 (85.5–92.4)
Urine LAM test only 44.9 (36.1–54.0) 88.1 (83.3–92.0) 67.1 (56.0–76.9) 74.8 (69.3–79.8)
Sequential or concurrent testing 83.5 (75.8–89.5) 84.7 (79.5–89.1) 74.6 (66.7–81.6) 90.5 (85.8–94.0)
Any microbiological test positivityc ≤50 Xpert MTB/RIF only 71.3 (60.6–80.5) 77.1 (70.7–82.4)
Urine LAM test only 66.7 (55.8–76.4) 74.3 (68.3–79.6)
Sequential or concurrent testing 92.0 (84.1–96.7) 92.3 (85.5–96.1)
≤200 Xpert MTB/RIF only 69.9 (62.3–76.9) 80.3 (76.4–83.8)
Urine LAM test only 52.2 (44.1–60.0) 71.9 (68.6–75.1)
Sequential or concurrent testing 87.1 (81.0–91.8) 90.5 (86.5–93.4)
a

Diagnostic performance of sputum-based Xpert MTB/RIF and urine-based Alere LAM in single, sequential, and concurrent testing strategies in HIV-infected hospitalized patients with CD4 counts of ≤50 and ≤200 cells/mm3 using sputum culture or any microbiological test positivity as a reference.

b

Sequential testing refers to performing Xpert in LAM-negative patients or LAM in Xpert-negative patients; concurrent testing refers to performing both Xpert and LAM concurrently.

c

Specificity and PPV could not be determined when any microbiological test positivity is used as a reference standard (as this will always equate to 100%).